CCIA
CRMD icon

Campbell & Co Investment Adviser’s CorMedix CRMD Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,398
Closed -$77.4K – 1089
2026
Q1 		$77.4K Sell
11,398
-93,430
-89% -$691K ﹤0.01% 1006
2025
Q4 		$1.22M Buy
104,828
+66,604
+174% +$736K 0.06% 487
2025
Q3 		$445K Buy
38,224
+24,923
+187% +$301K 0.03% 783
2025
Q2 		$164K Sell
13,301
-14,950
-53% -$165K 0.01% 1078
2025
Q1 		$174K Sell
28,251
-33,101
-54% -$343K 0.01% 959
2024
Q4 		$497K Sell
61,352
-16,993
-22% -$170K 0.04% 660
2024
Q3 		$633K Buy
+78,345
New +$424K 0.05% 615

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Campbell & Co Investment Adviser's CRMD Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of CorMedix (CRMD) in Q2 2026, closing a stake of 11,398 shares — an estimated $77.4K sold.

Campbell & Co Investment Adviser first reported a position in CRMD in Q3 2024 and held it in 7 quarters. The position peaked at $1.22M in Q4 2025. 193 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining CorMedix position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 11,398 CorMedix shares in Q2 2026, an estimated $77.4K.
  • Campbell & Co Investment Adviser first reported a position in CorMedix in Q3 2024 and held it in 7 quarters.
  • Campbell & Co Investment Adviser's CorMedix position peaked at $1.22M in Q4 2025.
  • 193 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.